Avelumab Plus Axitinib in Unresectable or Metastatic Type B3 Thymomas and Thymic Carcinomas
Sign in to PracticeUpdate
Only registered members have full access to PracticeUpdate content.
Additional Info
Disclosure statements are available on the authors' profiles:
The Lancet Oncology
From MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.
Avelumab plus axitinib in unresectable or metastatic type B3 thymomas and thymic carcinomas (CAVEATT): a single-arm, multicentre, phase 2 trial
Lancet Oncol 2022 Sep 09;[EPub Ahead of Print], F Conforti, PA Zucali, L Pala, C Catania, V Bagnardi, I Sala, P Della Vigna, M Perrino, P Zagami, C Corti, S Stucchi, M Barberis, E Guerini-Rocco, B Di Venosa, F De Vincenzo, N Cordua, A Santoro, G Giaccone, T Martino De PasFrom MEDLINE®/PubMed®, a database of the U.S. National Library of Medicine.